
Name of the Issue: Supriya Lifescience Limited

1 Type of Issue Initial Public Offer

2 Issue Size (Rs. Mn) 7000.00*

*Source: Prospectus dated December 21, 2021

3 Grade of issue along with name of the rating agency

Name NA
Grade NA

4 Subscription Level (Number of times) 73.9412*

*excluding Anchor Investor Portion and after removing multiple and duplicate bids

Source: Minutes for basis of allotment dated December 23, 2021

5 QIB Holding (as a %age of Outstanding Capital) as disclosed to the stock exchanges

Particulars	%age
(i) On Allotment **	23.81%
(ii) at the end of the 1st Quarter immediately after the listing of the issue (December 31, 2021)	18.21%
(iii) at the end of 1st FY (March 31, 2022)	14.86%
(iv) at the end of 2nd FY (March 31, 2023)	5.65%
(v) at the end of 3rd FY (March 31, 2024) *	Not Available

**Basis of Allotment (excluding pre-issue QIB holding)

* QIB Holding not disclosed as reporting for relevant period has not been completed.

6 Financials of the issuer

(Rs. Million)

Parameters	1st FY (March 31,2022)	2nd FY (March 31,2023)	3rd FY (March 31,2024)*
Income from operations	5,300.49	4,609.38	Not Available
Net Profit/(Loss) for the period	1,518.10	898.57	Not Available
Paid-up equity share capital	160.97	160.97	Not Available
Reserves excluding revaluation reserves	599.59	Not Available	Not Available

* Financials not available as reporting for the relevant years has not been completed.

7 Trading Status

The equity shares of Supriya Lifescience Limited are listed on both the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE") (and together with BSE the "Stock Exchanges")

The equity shares have not been suspended or delisted.

Particulars	Status
(i) at the end of 1st FY (March 31, 2022)	Frequently traded on BSE and NSE
(ii) at the end of 2nd FY (March 31, 2023)	Frequently traded on BSE and NSE
(iii) at the end of 3rd FY (March 31, 2024) *	Not Available

* Trading status not disclosed as the relevant fiscal years have not been completed.

8 Change in Directors of Issuer from the disclosures in the offer document

Particulars	Name of Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2022)	Not Applicable	
(ii) at the end of 2nd FY (March 31, 2023)	Mr. Manoj Dorlikar Mr. Balasaheb Sawant	Resignation Appointment
(iii) at the end of 3rd FY (March 31, 2024) *	Not Available	Not Available

* Changes in Directors of Issuer not updated as the relevant financial years have not been completed

9 Status of implementation of project/ commencement of commercial production

(i) as disclosed in the offer document	Not applicable
(ii) Actual implementation	Not applicable
(iii) Reasons for delay in implementation, if any	Not applicable

10 Status of utilization of issue proceeds

(i) As disclosed in the offer document

(Rs. Million)

Particulars	Amount which will be financed from Net Proceeds	Estimated Utilisation of Net Proceeds in Fiscal 2022	Estimated Utilisation of Net Proceeds in Fiscal 2023	Estimated Utilisation of Net Proceeds in Fiscal 2024
Funding capital expenditure requirements of the Company	923.00	436.13	436.13	50.74
Repayment and/or pre-payment, in full or part, of certain borrowings availed by the Company	600.00	600.00	-	-
General corporate purposes	359.52	150.00	209.52	-
Total	3,068.65	1,186.13	645.65	50.74

(ii) Actual utilization

(Rs. Million)

Particulars	Amount which will be financed from Net Proceeds	During the Quarter	At the end of the quarter	Total unutilised amount
Funding capital expenditure requirements of the Company	923.00	15.75	126.94	796.06
Repayment and/or pre-payment, in full or part, of certain borrowings availed by the Company	600.00	-	600.00	-
General corporate purposes (Incl. Offer Expenses)*	379.99	-	350.95	29.04
Total	1,918.74	15.75	1,077.89	825.10

Source: Stock Exchange Filings * On finalization of offer expenses, the amount proposed to be utilized for General Corporate Purposes is revised to INR. 379.99

(iii) Reasons for deviation, if any

Objects Name	Completion Date		Delay (No. of days / months)	Comments of the Board	
	As per Offer Document	Actual		Reason of delay	Proposed Course of Action
Capex	FY 21-22	FY 22-23	Approx. 12 Months	Due to Change in scope of work ,designing of equipment got changes which leads to delay in implementation	In FY 22-23 the same will be implemented.

(iii) Reasons for deviation, if any

11 Comments of monitoring agency, if applicable

(i) Comments on use of funds	Not applicable
(ii) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the Offer document	Not applicable
(iii) Any other reservations expressed by the monitoring agency about the end use of funds	Not applicable

12 Pricing Data

Designated Stock Exchange	BSE
Issue Price (Rs.)	274.00
Listing Date	28-Dec-21

Price parameters	At close of listing day - December 28, 2021	Close of 30th calendar day from listing day	Close of 90th calendar day from listing day - March 27, 2022	As at the end of the 1st FY after the listing of the issue (31st March,2022)		
				Closing price	High	Low
Market Price	390.35	489.40	470.35	492.9	601.9	376.8
Sensex*	57,897.48	57,858.15	57,593.49	58,568.50	61,765.60	47,705.80
Price parameters	As at the end of the 2nd FY after the listing of the issue (31st March,2023)			As at the end of the 3rd FY after the listing of the issue (31st March,2024) ⁽¹⁾		
	Closing price	High	Low	Closing price	High	Low
Market Price	190.70	515.35	170.05	Not Available	Not Available	Not Available
Sensex*	58,991.5	63,583.07	50,921.2	Not Available	Not Available	Not Available

* Being index of BSE, the designated stock exchange

(1) The pricing data is not disclosed as the relevant fiscal years have not been completed

13 Basis for Issue Price

Accounting ratio	Face Value per share (Rs.)	As disclosed in offer document*	At the end of 1st FY (March 31,2022)***	At the end of 1st FY (March 31,2023)**	At the end of 1st FY (March 31,2024)**	
EPS (Basic)	Company					
	<i>Consolidated</i>					
		2	16.92	18.86	11.16	Not Available
	Peer Group:					
	<i>Solara Active Pharma Sciences Ltd</i>	10	69.00	-16.18	Not Available	Not Available
	<i>Neuland Laboratories Ltd</i>	10	62.85	49.74	Not Available	Not Available
	<i>Aarti Drugs Ltd</i>	10	30.09	22.12	Not Available	Not Available
	<i>Wanbury Ltd</i>	10	(5.04)	25.29	Not Available	Not Available
<i>Divis Laboratories Ltd</i>	2	74.75	111.52	Not Available	Not Available	
Industry Avg		46.33	38.50	Not Available	Not Available	

	Company				
	<i>Consolidated</i>	2	-	26.13	17.09
	Peer Group:				
P/E	<i>Solara Active Pharma Sciences Ltd</i>	10	18.4	-41.11	Not Available
	<i>Neuland Laboratories Ltd</i>	10	27.8	20.64	Not Available
	<i>Aarti Drugs Ltd</i>	10	16.8	19.39	Not Available
	<i>Wanbury Ltd</i>	10	(13.2)	3.36	Not Available
	<i>Divis Laboratories Ltd</i>	2	65.3	39.49	Not Available
	Industry Avg		23.0	8.4	Not Available
	Company				
	<i>Consolidated</i>	2	46.04%	100.86%	Not Available
	Peer Group:				
RoNW	<i>Solara Active Pharma Sciences Ltd</i>	10	13.90%	-3.82%	Not Available
	<i>Neuland Laboratories Ltd</i>	10	10.25%	7.59%	Not Available
	<i>Aarti Drugs Ltd</i>	10	30.70%	19.78%	Not Available
	<i>Wanbury Ltd</i>	10	8.07%	-347.87%	Not Available
	<i>Divis Laboratories Ltd</i>	2	21.35%	25.24%	Not Available
	Industry Avg		16.85%	-59.81%	Not Available
	Company				
	<i>Consolidated</i>	2	36.75	10.69	Not Available
	Peer Group:				
NAV per share	<i>Solara Active Pharma Sciences Ltd</i>	10	443.3	2.36%	Not Available
	<i>Neuland Laboratories Ltd</i>	10	613.0	1.53%	Not Available
	<i>Aarti Drugs Ltd</i>	10	98.0	8.94%	Not Available
	<i>Wanbury Ltd</i>	10	(62.5)	-139.45%	Not Available
	<i>Divis Laboratories Ltd</i>	2	350.1	0.45%	Not Available
	Industry Avg		288.4	(0.3)	Not Available

Notes

* Sourced from Prospectus dated December 21, 2021.

**Not available as the relevant fiscal years have not been completed / information not disclosed

*** Annual Reports of the respective Company for the respective year

P/E based on basic EPS for the fiscal year / price on BSE for March 31, 2022

14 Any other material information

Particulars	Date
Dr. Shireesh Ambhaikar has agreed to extend his services on a retainership basis for a period of 2 years effective October 1, 2022 where he will be designated as Technical Head for certain projects of Supriya Lifescience Limited	September 27, 2022
The Board has in its meeting held today i.e. September 27, 2022 approved the appointment of Mr. Rajeev Kumar Jain as Chief Executive Officer and Key Managerial Personnel of the Company, who will be joining on October 3, 2022	September 27, 2022

Source: Stock Exchange websites i.e. www.bseindia.com and www.nseindia.com